BI 1181181

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

CompletedNCT02044406

Boehringer IngelheimHealthy

Start: 2014-01-31End: 2014-09-30Updated: 2014-10-08

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

WithdrawnNCT02345304

Boehringer IngelheimHealthy

Start: 2015-03-31End: 2015-05-31Updated: 2015-03-10